Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 490 Publications

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a NF7JeJNCeG:ydH;zbZMhSXO|YYm= MUO1NO69VQ>? M2fNV|I1cA>? MWXpcoRq[2G2ZYOgZUBxem:2ZXP0bZZmKGWoZnXjeEBi\2GrboP0JIV1d3Cxc3nk[S=> M{L5SlI3OTZ7MEe1
HGL5 MWnBdI9xfG:|aYOgRZN{[Xl? MkHvOVDPxE1? M4PodFI1cA>? MkTubY5lcWOjdHXzJIEheHKxdHXjeIl3\SCnZn\lZ5Qh[WejaX7zeEBmfG:yb4Pp[IU> NGPoN|YzPjF4OUC3OS=>
HepG2 NXzTRVRGSXCxcITvd4l{KEG|c3H5 M2f3WFIx|ryP NYrWc5RvOWh? NH60bFdifHSnboXheIVlKHSqZTDhdI9xfG:2aXOgbY5lfWO2aX;uJI9nKEmLST2xNOKh NYXyd|JjOjZzNkS3PVU>
BEL-7402 M2fLTmFxd3C2b4Ppd{BCe3OjeR?= M2DjVlIx|ryP NUK3[3RmOWh? M{DTWoF1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> NVr0fWRKOjZzNkS3PVU>
CEF MWnLbY5ie2ViQYPzZZk> NYPWbppvOCx|Mzy2O{wyODEQvF2= MYOxOY1qdg>? NULIdnVJ\G:5bj3y[Yd2dGG2ZYOgVHIh\W68eX3lJIFkfGm4aYT5JJRwKDRy78{FJIF1KDFyMN88US=> MXmyOlExOjN|OR?=
SP2/0 MXTBdI9xfG:|aYOgRZN{[Xl? MWGxNFDPxE1? NGXjW5UycA>? NFfSWpZFVVOR NYPsSW9b[myxY3vzJJRp\SCjcH;weI9{cXNib3[gV3AzNzBiY3XscJM> MmnKNlYxPzR5M{K=
HUVEC-2c M3zyOGFxd3C2b4Ppd{BCe3OjeR?= MUi1NO69VQ>? Mk\uOog> NH30RZpl\WO{ZXHz[YQhfGinIH;4MWxFVC2rbnT1Z4VlKGG3dH;wbIFogQ>? NX3IfpVOOjZyMkG3Nlk>
U1 NIXucllCeG:ydH;zbZMhSXO|YYm= NETJcHcxNTFyMN88US=> NV3oWod1Omh? M2DwS5Jm\HWlZYOg[JJ2\y2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgd5Vje2WzdXXueEBJUVZvMTDy[ZBtcWOjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmjUNlU6QDB7NEK=
ACH-2 MofuRZBweHSxc3nzJGF{e2G7 Ml;iNE0zODEQvF2= M2XJelJp M{TlOpJm\HWlZYOg[JJ2\y2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgd5Vje2WzdXXueEBJUVZvMTDy[ZBtcWOjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX2yOVk5ODl2Mh?=
U1 NUDLfIcxU2mwYYPlJGF{e2G7 MUexNFDPxE1? MYOybC=> NVnjU3VbcW6qaXLpeJMh[2G|cHHz[U0{ MV[yOVk5ODl2Mh?=
A549/V16 MYPBdI9xfG:|aYOgRZN{[Xl? MnvZOVDPxE1? MX[xbC=> MoLhdoVxemW|c3XzJHRIN1SPLXnu[JVk\WRiYYDvdJRwe2m| MWeyOVk1PjB|Mx?=
SGN NIG3fHpCeG:ydH;zbZMhSXO|YYm= M37QcFIxdU1? M{joWFQ5cA>? MmrjbIF{KG6xIHnu[ox2\W6lZTDvckBCUUZuIHPhcJBicW5iZYjwdoV{e2mxbjDvdkBk\WyuIHHwc5B1d3Orcx?= MlLuNlU5PzR4M{O=
HCT116  MVzBdI9xfG:|aYOgRZN{[Xl? MVi1NO69VQ>? NHTDb40zcA>? M{fMb4lvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgSGRXWA>? M4TUOVI2QDZ6OEG4
DTK-SME NYfzfnI{SXCxcITvd4l{KEG|c3H5 NFjuRXc2OM7:TR?= M1TRfVJp NF3vVZhFVVOR MkiydIFzfGmjbHz5JIlvcGmkaYTzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDieZBqfmGlYXnu[S=> NXTDXVFGOjV6NEO4PVc>
HL-60 MoT0RZBweHSxc3nzJGF{e2G7 NXPFcndDPTEQvF2= NUX0RoFHPDiq NVvPbGFjemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCVS1mtTWkhfHKnYYTt[Y51yqB? NVzFb3M{OjV6MkSwOFM>
U937 NFWxUpRCeG:ydH;zbZMhSXO|YYm= MYK1NO69VQ>? M3X5TlQ5cA>? NYLzbpRJemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCVS1mtTWkhfHKnYYTt[Y51yqB? NYDOcIVVOjV6MkSwOFM>
A549 MnP2RZBweHSxc3nzJGF{e2G7 MYKyNEDPxE1? Mnv5NlRp M2rndpJm\HWlZYOgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhUE[FUDD0doVifG2nboS= NUH3blJUOjV5OUSxOFk>
HeLa M1j3OmFxd3C2b4Ppd{BCe3OjeR?= M2rQWlEx|ryP M2PY[|Q5cA>? Ml;p[IVkdGmwZYOgeIhmKHKjdHWgc4Yh[XCxcITvd4l{KGS{YX3heIlk[WyueR?= NFHRPIozPTd5MkW0OS=>
SGC-7901 MXXBdI9xfG:|aYOgRZN{[Xl? NYn0dXhZOjEEoN88US=> NWr4OphZOWh? MnHMbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDvfIFtcXCuYYTpci=> MoTMNlU4PjdyN{[=
MCF-7 NXqwbY46SXCxcITvd4l{KEG|c3H5 MYSxNO69VQ>? MnHGNog> NIXoeFBqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JFND Mn75NlU4OjJzMUS=
A549 MYDBdI9xfG:|aYOgRZN{[Xl? NV;0fZplOTBizszN NG\tZo4zPGh? MYjEUXNQ MlvadJJwdW:2ZYOgTGJENXS{ZXH0[YQhSTV2OTDj[YxtKHO3co\peoFtKCZiYYT0[Y52[XSnczD0bIUh[2ynYY\l[EBRSVKSIHX4dJJme3Orb36= M4D1XFI2Pjh|NU[4
U87 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO4cng2OM7:TR?= M4n0PVFp NF31WWpz\WOxdnXyd{Bk\WyuIHfyc5d1cCCocn;tJHROYiC2cnXheI1mdnR? MmPXNlU3QDF4Nki=
Neocortical Neuron NYHUZXBOVmW3cn;0c5hq[2m2eTDBd5NigQ>? MUixNFDPxE1? M2LO[FFp M3ri[IFvfGGpb37pfoV{KEixaXHtbYRmKEFvSX7keYNm\CCQZYXyc5RwgGmlaYT5 MkjxNlU3PzVyMEG=
Primary human placental cytotrophoblasts NVvnTpZiSXCxcITvd4l{KEG|c3H5 NFTzcY4{OM7:TR?= MnTsNlRp Ml;uSG1UVw>? M2fM[5JmfmW{c3XzJJRp\SCrbnjpZol1cW:wIH;mJFEy|rJvSGPENkBjgSC2cnnjcI9{[W8EoB?= NInONWUzPTZ2MkW5Ni=>
MM Mn3KRZBweHSxc3nzJGF{e2G7 M{HmZlUx|ryP MXOyNI1qdg>? M17vWpBienSueTDpcohq[mm2czDTTGsucW6mdXPl[EAh[2WubDDk[YF1cA>? MY[yOVU{ODB7OB?=
DLD1 NXvhSGhVSXCxcITvd4l{KEG|c3H5 NVm5T3ZtOjEEoN88US=> MkjRNYg> MYDwZZJ1dHlicnX2[ZJ{\XNiY3XscEBieG:ydH;zbZMh[2G3c3XkJIJ6KFeVUEG= NGHlUVEzPTV{NEK0Oi=>
MDA-MB-231 NInOUopEgXSxdH;4bYNqfHliQYPzZZk> MWOxNO69VQ>? M1XNWFFp MUXheYdu\W62czDj[YxtKGSnYYToJIFnfGW{IFPIWWEhfHKnYYTt[Y51 MXiyOVUzOTVyMR?=
MKN28 M4W3T2Fxd3C2b4Ppd{BCe3OjeR?= M1fsPVEx|ryP MkfBN|BucW5? NGXoNWFFVVOR M2nQT4lvcGmkaYTzJHRPTi4QsTDwcJV{KEOKWD3pcoR2[2WmIHHwc5B1d3Orcx?= MVmyOVUyOzl4MB?=
HL-60 Mn:1R5l1d3SxeHnjbZR6KEG|c3H5 NHvYTpcyODEQvF2= MXixbC=> M4jrS2ROW09? MkXrxsBqdXC{b4\ld{B3cWGkaXzpeJkhd2ZiVFPORZMufHKnYYTl[EBk\Wyucx?= NV7HO3pCOjV3MEK5N|I>
AGS MXvBdI9xfG:|aYOgRZN{[Xl? MmnPNVDPxE1? M4jhOVFp M3TLfpBz\X[nboTzJIN2emO3bXnuMYlv\HWlZXSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[U0{NCBvODygZY5lKC17IIDyc5RmcW6| MV2yOVQ6OjJzNB?=
A549  NUDIdXBFSXCxcITvd4l{KEG|c3H5 NYLne|g4OTEQvF2= NFXvR5EzPGh? NXy5WHFj[myxY3vzJGROSVNvaX7keYNm\CClbHXheoFo\SCxZjDjZZNx[XOnLUOgZY5lKFCDUmCgZY5lKGGyb4D0c5Rq[yClZXzsJIRm[XSq MkC1NlU1OzR7OEm=
INS-1 M4jKfWFxd3C2b4Ppd{BCe3OjeR?= NHG1c3g2OM7:TR?= M2jmV|Zp MmPZSG1UVw>? NUfnZ5U{\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGWjcnz5JIFxd3C2b4TpZ{Bk\Wyuc9Mg Ml7ZNlU1OzB6OUe=
Primary hepatocytes  NIXBXW1CeG:ydH;zbZMhSXO|YYm= NUPCPZJIPTEQvF2= NV6ydJNWOTiq MmLsbY5pcWKrdIOgZZBweHSxc3nzJI9nKGincHH0c4N6fGW|IHnu[JVk\WRiYomgRYN1KERiYX7kJHRPTi4QsR?= NXnITnp{OjV2MEe1N|g>
L929-A  MoTiR5l1d3SxeHnjbZR6KEG|c3H5 NYr4[XVGOjEEoN88US=> MlPTNlRp MlTwbY5pcWKrdIOgWG5H|rFvaX7keYNm\CClZXzsJIRm[XSq NYDGPWFvOjV|OUi1OFA>
L929-N MWDDfZRwfG:6aXPpeJkhSXO|YYm= M4rDSlIxyqEQvF2= NIDibFEzPGh? MWLlcohidmOnczDk[YF1cCC4aXGgZZV1d2O{aX7lJHRPTs7zIIDyc4R2[3Srb36= NFnhW5QzPTN7OEW0NC=>
Cytotoxicity Assay NYjXc|J5S2WubDDWbYFjcWyrdImgRZN{[Xl? NW\TZVB1OjEQvF2= NWe0TppOPDiq MnKwdJJmfmWwdDDNTG1FNWmwZIXj[YQh[2WubDDk[YF1cA>? NWDVdWtQOjV|OUKxNVY>
COS7 NWK4d5VDU2mwYYPlJGF{e2G7 NGfiZpMyOM7:TR?= NFOxUmszPGh? MXXpcoNz\WG|ZYOgZ4F{eGG|ZTCzM|ch[WO2aY\peIlmew>? Mmi3NlU{QDRyMkW=
COS7 MYfBdI9xfG:|aYOgRZN{[Xl? NV;CTVlmOTEQvF2= NGDKRYI1QGh? NH;udJNx[XK2aXHscJkheHKndnXueIVlKE[FMUCxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MnnCNlU{QDRyMkW=
A375 MYfBdI9xfG:|aYOgRZN{[Xl? NYqxdmhMOzEQvF2= NGHwZWIzcA>? NYnjclk4eHKndnXueJMhfGinIHTyeYcucW6mdXPl[EBRSVKSIHPs[YF3[Wen MYSyOVM4PjFzNR?=
A549 NYHOXowxSXCxcITvd4l{KEG|c3H5 MmDtOVDPxE1? NIr2cJYzPGh? NH7Ob4xz\X[ncoPld{BzcWKxc3;t[UBjcW:pZX7ld4l{KGGwZDDhdI9xfG:|aYOgZ4F2e2WmIHL5JEBEcGmsb37n[IFv MlzONlU{PDl5OEG=
A549 NFfzR5ZCeG:ydH;zbZMhSXO|YYm= NHnLR4YzNjVvMkZOwG0> M{TnW|Fp NVTZNld1\GWlcnXhd4V{KHSqZTDwc5B2dGG2aX;uJI9nKGGyb4D0c5Rq[yClZXzsd{Bl\XCnbnSgc44h[2:wY3XueJJifGmxboO= M1zC[lI2OzR{NEK3
 NBL-W-S  MWLBdI9xfG:|aYOgRZN{[Xl? MYe1NO69VQ>? NYXxcnh5OWh? Morj[pVtdHlicnXzZ5VmeyClZXzsJJZq[WKrbHn0fUBi\nSncjDHRW5VNTZzIITy[YF1dWWwdB?= NUXzNIdIOjV|MkOyNlI>
Caki-1  NUDPW5ZvSXCxcITvd4l{KEG|c3H5 M1j3SFQx|ryP NWrYUWRtPDiq NFy5b2Nz\WS3Y3XzJJRp\SCwdX3i[ZIhd2ZiQX7u[ZhqdiCYLYDvd4l1cX[nIHPlcIx{ MUWyOVI4QTF7MR?=
769-P M4DJcWFxd3C2b4Ppd{BCe3OjeR?= NVLxVpFRPDEQvF2= NXPHeFBmPDiq M33WfZJm\HWlZYOgeIhmKG63bXLldkBw\iCDbn7lfIlvKFZvcH;zbZRqfmViY3XscJM> NIHyOYQzPTJ5OUG5NS=>
H9c2 MonMRZBweHSxc3nzJGF{e2G7 MmDhOVDPxE1? MWmxbC=> NV;YO3BmcW6qaXLpeJMhTE:[LXnu[JVk\WRiY3HzdIF{\SB|IHHjeIl3[XSrb36gZpV1KG6xdDD0bIUhdG:|czDv[kBk\Wyucx?= NUSwepd5OjV{OEO4NVk>
K562 NYjlWIF[SXCxcITvd4l{KEG|c3H5 MVW1NO69VQ>? NXnTOG1zPGh? Mn3XbY5pcWKrdIOgToFkNUFvaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> NVHSZ2ZmOjV{NEG2NVk>
L929 M2nYfGFxd3C2b4Ppd{BCe3OjeR?= MV:xNO69VQ>? MVu2bC=> MX3pcoR2[2W|IH7lZ5JweHSxc3nzJJdqfGhiVF7G MnrxNlUyQTV4NkC=
A549 Ml\0RZBweHSxc3nzJGF{e2G7 NVjRVpY4OTEQvF2= M1KxS|Np M4fnNJJm\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3H1d4VlKGK7IGDRVS=> NWG1SndzOjVzNkG2PVk>
MCF-7 NVr2RpNLSXCxcITvd4l{KEG|c3H5 M1H5eVIx|ryP NWixTY5vOmh? MVTk[YNz\WG|ZYOgT2RTNXOrUl7BMYlv\HWlZXSgZZBweHSxc3nz NILaO2QzPTF6MkK0NC=>
OS MnvnRZBweHSxc3nzJGF{e2G7 MojCNlAwPDEQvF2= NYnwR4JyPzKq MVrpcohq[mm2czDPV{Bk\WyuII\pZYJqdGm2eTDy[YR2[3Srb36gZpkhSzZiY3XyZY1q\GV? M4TTWlI2OTV{M{m5
HUVECs NXTxXoVxSXCxcITvd4l{KEG|c3H5 MlTONVDPxE1? NYnKU3J{Omh? NF\LeY/DqGmwaHnibZR{KGGyb4D0c5NqeyCjbnSg[oFkcWyrdHH0[ZMh[XW2b4DoZYd6KGmwIFTFUnYzNWmwZnXjeIVlKEiXVlXDdy=> NWPLSoZVOjVzM{i3NFM>
EA.hy926 MWPBdI9xfG:|aYOgRZN{[Xl? MVexNO69VQ>? NUjsbpB4Omh? M{Hk[OKhcW6qaXLpeJMh[XCxcITvd4l{KGGwZDDmZYNqdGm2YYTld{BifXSxcHjh[5khcW5iRFXOWlIucW6oZXP0[YQhTUFwaIm5NlY> M3zwcVI2OTN6N{Cz
Ebs NIXUfWFCeG:ydH;zbZMhSXO|YYm= MXuxNE0yODEQvF2= MWiyOIg> Ml3vxsBOVVSVIHflcoVz[XSrb36gdoF1\SCmZXPy[YF{\WRiYYOgeIhmKGOxbnPlcpRz[XSrb36gc4Yhgi2YQVSu[o1sKGmwY4LlZZNm\A>? M4PvUlI2OTN2OEG3
Jurkat NVnPcI5FSXCxcITvd4l{KEG|c3H5 NGXlXlMzOM7:TR?= NFiwflgzPGh? NGrjeYZFVVOR MV3wZZJ1cWGubImgbY5pcWKrdDDj[YxtKGSnYYToJI9nKEq3cnvheEBk\WyuczDpcoR2[2WmIHL5JFExODV6LV[0JINwdWKrbnXkJJdqfGhiVmDBxsA> Mmr1NlUyOjB5MkO=
K562 NIe3epRCeG:ydH;zbZMhSXO|YYm= MWCwMlEuOc7:TR?= NWjVeJZ4OWh? MX\pcohq[mm2czDjcIVifmGpZTDv[kBJW1B7MDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVTkRZplOjVzMUmxPFg>
IMR-32 MV\BdI9xfG:|aYOgRZN{[Xl? Ml[yOFDDqM7:TdMg MWqybC=> M4PLfYRm[3KnYYPlJIlvKGGyb4D0c5Rq[yClZXzsd{Bkd22yYYLl[EB1dyCWLUKgeI95cW5? NEXq[GwzPTB6NEe1OS=>
RPMI 8226 M{PnbGFxd3C2b4Ppd{BCe3OjeR?= M{jMeFExOM7:TR?= NH;U[HAycA>? NELuW3hidG2xc4SgZ49ueGyndHXsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?= NYTNU2RoOjVyM{e4OVE>
U266  NIHTVYJCeG:ydH;zbZMhSXO|YYm= MnfWNVAx|ryP NFfQOY8ycA>? NILoXmpx[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= NYrqbIRPOjVyM{e4OVE>
H929  M1XFc2Fxd3C2b4Ppd{BCe3OjeR?= NYrQ[I5GOTByzszN NYTiU|BNOWh? NYHpRVVSeGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x MX:yOVA{Pzh3MR?=
MM.1S  M{W2WGFxd3C2b4Ppd{BCe3OjeR?= NYXwe3JvOTByzszN M3r2ZlFp MkTj[YZncWOrZX70cJkheHKndnXueJMhe2:{YX\lcoljNWmwZIXj[YQh[2WubDDk[YF1cCClb33ibY5mKHerdHigcoVkem:|dHH0bY4uOQ>? M4fjZlI2ODN5OEWx
C6 NFHuTIFCeG:ydH;zbZMhSXO|YYm= M37HdFUx|ryP MVm0PIg> MYPwdoV3\W62czD0bIUhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDjZZV{\WRiYomgdJJm\26nbn;sc45m Mln1NlUxOTN2N{m=
AGS MWTBdI9xfG:|aYOgRZN{[Xl? M4P5W|Ux|ryP MUeyOIg> NULFdm9i[WKxbHnzbJMh|rJvbHHwZYNpd26nLXnu[JVk\WRiY3XscEBl\WG2aDDhcoQhcW6qaXLpeIVlKGe{b4f0bC=> MUmyOVAxQTZ7OB?=
HeLa  Mn7jRZBweHSxc3nzJGF{e2G7 MlvYOFDPxE1? M3;RR|I1cA>? MoTDbY5pcWKrdIOgeIhmKGmwY4LlZZNm\CCjcH;weI9{cXNiaX7keYNm\CCkeTDzbXJPTjF{MR?= M3fm[lI1QTJ6Nki1
THP-1  NFjXNYVCeG:ydH;zbZMhSXO|YYm= NYLDOGdFOTEQvF2= NX3qRWNQOWh? MlPWdoVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBCVEFvU1TUxsA> MUGyOFkzOzZ3Mx?=
P815  NXfKdnRuSXCxcITvd4l{KEG|c3H5 MnTxNVAxKML3TR?= NXvT[XE2OTKq M4nLSmROW09? MWPpcohq[mm2czD2bZJ2ey2rbnT1Z4VlKGGyb4D0c5Nqew>? NIi0dJgzPDl{M{K3Ny=>
HCT116 NGPMTYlCeG:ydH;zbZMhSXO|YYm= NH73ToczOM7:TR?= MXyyOIg> NEfPepZi[nKxZ3H0[ZMhd2ZiVGGtbY5lfWOnZDDhdI9xfG:|aR?= M13xTlI1QDlyNES5
SW1116  Mo\PRZBweHSxc3nzJGF{e2G7 NXfIWYxwOTBiwsXN MlfuNYg> M4[1WmROW09? NV\lVZFbemW|dILhbY5{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkh\2WoaYTpcoljKHCudYOg[IVkcXSjYnnu[S=> NVjYS5pVOjR6N{SyPFY>
LOVO NWTy[YpxSXCxcITvd4l{KEG|c3H5 NVrHWJJTOTBiwsXN NUfYSYhqOWh? MYXEUXNQ NWfEXok6emW|dILhbY5{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkh\2WoaYTpcoljKHCudYOg[IVkcXSjYnnu[S=> MWWyOFg4PDJ6Nh?=
SNU449  Mk[1RZBweHSxc3nzJGF{e2G7 NWW1SXBXOjEQvF2= M1rCbFQ5cA>? MkPYSG1UVw>? NFTheJVl\WO{ZXHz[ZMhdWmULUS1NU1qdmS3Y3XkJIFxd3C2b4TpZy=> NYXyRY1uOjR6NEG2N|g>
Caco-2 NUnpeY5kSXCxcITvd4l{KEG|c3H5 MmSwOFDjiIoQvF2= Ml\DOIg> NFfWb2RxemW4ZX70d{BUXC15LXnu[JVk\WRiWl:tNUBkcGGwZ3XzJIFv\CCWRWKg[JJweA>? NYTNbWZVOjR6MkKxPFM>
macrophage MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUiwMVIxOM7:TR?= M361TFI1cA>? NG\qSIVqdmS3Y3XzJHRPTi1iYX7kJHJqeDNvZHXw[Y5l\W62IH7lZ5JweHSxc3nzJIlvKG2jY4LvdIhi\2V? NWn6e3hOOjR5OUm1OlU>
AGS  NF62eHFCeG:ydH;zbZMhSXO|YYm= MlrnNlDPxE1? NYm2b5FPOTKq M4nocGROW09? NF;zfXlz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIlvKHKnc4DvcpNmKHSxIITo[UBGfE:DYzDmdoFkfGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYDMVGtZOjR5OEm3NFM>
LCC9  MnrlR4VtdCCYaXHibYxqfHliQYPzZZk> MnrENVAx|ryP M{DR[FVl MUjicI9kc3NiY3XscEBl\WG2aDDpcoR2[2WmIHL5JINwdWKrbnH0bY9vKExzNzDhcoQh[2iub4LvdZVqdmV? NXTEO2ozOjR5OEWyOVY>
U937  NFfOUJVv\WO{b4D0c5NqeyCDc4PhfS=> M2fscFExyqEQvF2= MoP6N|DDqG2rbh?= NH\GTHNqdmS3Y3XzJI5m[3KxcITvd4l{KGOxbXLpcoUhf2m2aDDUUmY> NX\uWopUOjR5N{O3OVY>
T cell M{T1eWNmdGxicILvcIln\XKjdHnvckBie3OjeR?= MkTPNE0yODEQvF2= NF\1PWc4Omh? NIXBOohKSzVyPUewJO69VSxiaX7obYJqfHNiYX70bU1ETDNvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjDpckBRSk2Fcx?= M2e5dlI1PzZ6N{C3
HeLa  MXzBdI9xfG:|aYOgRZN{[Xl? M1v2WVUx|ryP NUnzNJJsPzKq MkDYSG1UVw>? Mn7CdJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2:vcH;1coR{yqBz4pETOS=> Ml7qNlQ4PTR5OE[=
HeLa  M3HiXmFxd3C2b4Ppd{BCe3OjeR?= M4LDXlExOM7:TR?= NF;Lc5MzPGh? NVexRWRGe3WycILld5NmeyC{YYTlJI9nKGOnbHyg[IVifGhiaX7keYNm\CCkeTDveoVz\XiycnXzd4lwdiCxZjDHOVlUKG:{IFe3NXIheDF3MHfseYVlyqB? Ml;UNlQ4OjJ2Nki=
IEC-6  NWPkbI1OSXCxcITvd4l{KEG|c3H5 MUSxNO69VQ>? Mn7KNlRp M2DvW5Bz\X[nboTzJHRk\EFvaX7keYNm\CClYYPwZZNmNTNiY3zlZZZi\2ViYX7kJO6zNWOjdHXubY4h\GWpcnHkZZRqd25? M2q2UVI1PzFzNUex
HCT116 NWPtUI9DSXCxcITvd4l{KEG|c3H5 MnL0NlDPxE1? M1OwSlI1cA>? NUXxOZVlcW6qaXLpeJMhfGinIHPlcIwh[XCxcITveIlkKGmwZIXj[YQh[nliWVzUNlA2 MnzTNlQ4OTN6MUK=
L02 MkX1RZBweHSxc3nzJGF{e2G7 MUiyNO69VQ>? MVyxbC=> MVLwdoV3\W62czD0bIUh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBOTUiS NYn3fWZ3OjR5ME[0OlE>
A375 NHG0dnhCeG:ydH;zbZMhSXO|YYm= NV;H[o9tOjEQvF2= M4XTWFI1cA>? MlPtdoV3\XK|ZYOg[IlkcXS{aX7vcoUhSi2rbnT1Z4VlKGGyb4D0c5Nqew>? MUmyOFY6QTFzMR?=
HDPC MVvBdI9xfG:|aYOgRZN{[Xl? NXjM[|FCPTEEtV2= NYH2bo94OjSq NHnoVW1qdmirYnn0d{BPVy2rbnT1Z4VlKGGyb4D0c5Nqew>? NXHCc2tIOjR4M{S1PVM>
A549 M{j2TGFxd3C2b4Ppd{BCe3OjeR?= M33EWVUxyrWP NITDO5IzcA>? MXTEUXNQ NHLncFRxemW4ZX70d{B1cGViaInwc4RqeGyxaXSgSG5CKGOxboTlcpQheGijc3WgbY5lfWOnZDDifUBk\XCqYXzvZ4hzd22rbh?= MmHuNlQ2QDhzM{W=
 BV-2 MkLGRZBweHSxc3nzJGF{e2G7 M4PRc|Ix|ryP NXnkS3ZKOmh? MY\zeZBxemW|c3XzJHVXNWmwZIXj[YQh[2i{b33heIlvKGW6dIL1d4lwdiCjbnSg[Ilt[XSrb36gc4YhfGinIH71Z4xm[XJiZX72[YxweGV? MXOyOFU2QDFzOB?=
HT-29  Mme1RZBweHSxc3nzJGF{e2G7 NV7YVWpvPTEQvF2= M3;kWFQ5cA>? M2PzeIJtd2OtczD0bIUh[XCxcITvd4l{KGmwZIXj[YQh[nlia3HlcZBn\XKxbB?= M3XP[VI1PTR7MUe1
A549 MYDBdI9xfG:|aYOgRZN{[Xl? NWn5bmVYPc7:TR?= M2jwelI1cA>? MmPDd5VxeHKnc4Pld{A3\cLiKFLLNVAxPDBrLXnu[JVk\WRiYYDvdJRwe2m|wrC= MnPZNlQ2Ojl6N{G=
MIA-PaCa-2 MX7BdI9xfG:|aYOgRZN{[Xl? NV\JcVVNOjSq M{DCboJtd2OtczDjcIVifmGpZTDv[kBk[XOyYYPlMVMhcW6mdXPl[EBjgSCkb4ToJGEuPDR|NkW0JIFv\CCyYXPsbZRigGWu MlnwNlQ2OTB7OUK=
Caki-1 MWfBdI9xfG:|aYOgRZN{[Xl? NIW2OWYzOM7:TR?= Mme2NYg> MnHFbY5pcWKrdIOgV2NRNWmwZIXj[YQh[XCxcITvd4l{ MYKyOFUxPDZ6MR?=
CLL MlTkRZBweHSxc3nzJGF{e2G7 M{jZd|I2|ryP M2Lh[FFp MX7wZZJ1cWGubImgZoxw[2u|IF3MUlIzOzhvaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> NGP4c2wzPDR4N{[zOC=>
SGC-7901 NFLFWlJCeG:ydH;zbZMhSXO|YYm= MVixNO69VQ>? Ml:3NlRp MVTwdo9ud3SnczD0bIUhS0eLST3pcohq[mm2ZXSgZ4VtdCCpcn;3eIghcW5iU1fDMVc6ODFiY3XscJM> NHjITYwzPDR3NES4PC=>
k1735 NEjBXpNCeG:ydH;zbZMhSXO|YYm= M1PsUlIx6oDLzszt MWK0bC=> MYjpcohq[mm2c9MgV4FtdW:wZXzsZU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NHr4bmQzPDR3MUGxOi=>
HaCaT  M3u0XmFxd3C2b4Ppd{BCe3OjeR?= NIK4Sm0yODEQvF2= M2fye|Fp NVf0dodI[my3boTzJHVXSi2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDIZWNiXCClZXzsdy=> M2f6eVI1OzV4OUm3
podocytes M3zpbGFxd3C2b4Ppd{BCe3OjeR?= NUfHZlRIOjByzszN NFe0[2g3cA>? M{PmeolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDNuND3ES2U> NED4V|QzPDN|N{e3Oy=>
 KB NVjFN5BVSXCxcITvd4l{KEG|c3H5 NH3mNJY2OM7:TR?= MXWyOIg> MVzpcohq[mm2czDMbYNwNUFvaX7keYNm\CClYYPwZZNmNTNiYX7kJHBCWlBiYXP0bZZifGmxbh?= MUmyOFM{PzR7Mh?=
 HepG2  MnXURZBweHSxc3nzJGF{e2G7 Mm\KNVDPxE1? MkDxNlRp NWTG[IlIemWmdXPld{B3cW2nboTpckBkdGWjdnHn[UBk[XW|ZXSgZpkhVFCV MUKyOFMzPThzNh?=
fetal rat lung fibroblasts  M2\OUGtqdmG|ZTDBd5NigQ>? NEDKfmc5OM7:TdMg NITWSWIycA>? MknabY5pcWKrdIOgR4F{eGG|ZT2zJIFkfGm4aYT5xsA> M2L1SlI1OzF2MUO1
PDL fibroblasts NXjGfGJ{U2mwYYPlJGF{e2G7 NV7keYo4QDEQvF5CpC=> NXvBXFFEOWh? NVTUOmEycW6qaXLpeJMhS2G|cHHz[U0{KGGldHn2bZR6yqB? MmLkNlQ{OTRzM{W=
MB49 NXLXXpliSXCxcITvd4l{KEG|c3H5 MWSyNO69VQ>? M1LQd|Fp Mlj4doV3\XK|ZYOgR20ucW6mdXPl[EBk\WyuIHTlZZRp MljCNlQzQDJ2M{O=
5637 NH7ZZmVCeG:ydH;zbZMhSXO|YYm= MXyyNO69VQ>? MYmxbC=> NWXrZoE1emW4ZYLz[ZMhS01vaX7keYNm\CClZXzsJIRm[XSq NVnlbndoOjR{OEK0N|M>
A549  M1;WOmFxd3C2b4Ppd{BCe3OjeR?= M33BdlExOM7:TR?= MWS0PIg> NGjsVot{fXCycnXzd4V{KHSqZTDhdI9xfG:|aYOgZ4F2e2WmIHL5JJBqeGW{aX7lxsA> M4jkelI1Ojd{MkCx
MCC-2 M3fGXWFxd3C2b4Ppd{BCe3OjeR?= MWCyNEDPxE1? M{n5cFZp NYiyWVJuTE2VTx?= NX3Udol3[myxY3vzJIlv\HWlZXSgZpkhe3SjdYLvd5BwemmwZTDhdI9xfG:|aYOgZ4VtdCCmZXH0bC=> NVfUTVJXOjR{NkK2OVg>
ADF NIDrdlRCeG:ydH;zbZMhSXO|YYm= M2fNdlQx|ryP NXf2XVJxPmh? NHzye5pqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> NIrvXVYzPDJ{OEKzNi=>
 U373  MYHBdI9xfG:|aYOgRZN{[Xl? Mm\3OFDPxE1? MlXPOog> MX3pcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkcGWvb4To[ZJieHlicHz1d{BbdkOuMh?= MVqyOFIzQDJ|Mh?=
RKO-HIPK2i NIfmcGxCeG:ydH;zbZMhSXO|YYm= MmDpOFDPxE1? M2exWVZp NUHPVGtDcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JJBtfXNiWn7DcFI> NVXhfVdlOjR{MkiyN|I>
HEC-1B MWXBdI9xfG:|aYOgRZN{[Xl? MnHZNlDPxE1? NUDNSmxxOWh? NX;ne5Y6emWmdXPld{BVWC2rbnT1Z4VlKGGyb4D0c5Nqe8LiY3HzdIF{\S1|IHHu[EBk[XOyYYPlMVk> Mle5NlQzOTN|NUi=
4T1 NIPsd2hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYSyMlUuOTEQvF2= MmrGOIg> NU\tZnZzTE2VTx?= NW\uZVd1emW|Y4Xld{B1cGViY4n0c5RwgGmlaYT5JI9nKDSWMTDj[YxteyCrbnT1Z4VlKGK7IGPQSHQhcW5iYTDjc45k\W62cnH0bY9vKGSncHXu[IVvfCCvYX7u[ZI> NIDTV2EzPDJyNkG2NS=>
OS  M4nlRWFxd3C2b4Ppd{BCe3OjeR?= NHL5WVMzOM7:TR?= MYi0bC=> NGPJRnpqdmirYnn0d{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgVGRV M3u0b|I1OjB2OUO3
RPE NYPje3ltSXCxcITvd4l{KEG|c3H5 NVrVeWpzOTByzszN M4q0V|Q5cA>? NYLRTlhHeGG{dHnhcIx6KGmwaHnibZR{KHSqZTDjZYxx[WmwLUGgZY5lKC1{IHHjeIl3[XSrb36gZZMhf2WubDDhd{B1cGViY3HzdIF{\SCjY4TpeoF1cW:w M{Swd|I1OjB{MEWy
UD29a M{XoN2Fxd3C2b4Ppd{BCe3OjeR?= NWLaW4J{PTEQvF2= MlWwNlRp NELuSJZqdmirYnn0d{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgUnVVOw>? NXf0[HZ6OjRzOUC1O|Q>
SH-SY5Y  MWTBdI9xfG:|aYOgRZN{[Xl? M4fNR|Ex|ryP MkDXNlRp MofqZZR1\W63YYTld{Bk[XOyYYPlJIFkfGm4YYTpc44h[W6mIHPlcIwh\GWjdHigbY5lfWOnZDDifUBJVkVvMlTH M1zPdVI1OTR3NE[z
HeLa  MlPZRZBweHSxc3nzJGF{e2G7 M{fXdVExNzJyzszN NVnpbmpmOjSq MV\pcohq[mm2czD0bIUh[WO2aY\peJkhd2ZidHjlJI1icm:{aYT5JI9nKHSqZTDt[Y1j\XK|IH;mJJRp\SClYYPwZZNmNW[jbXnsfS=> M2m2VlI1OTN5Mk[2
SCCVII  NFTYV21CeG:ydH;zbZMhSXO|YYm= NFfrTYgzPc7:TR?= NXLCSottOWh? MXjpcohq[mm2czD0bIUh[2WubDDrbYxtcW6pIHHmeIVzKGSjc3H0bY5q[g>? M1\1[|I1OTJ4NE[0
RAW 264.7 M3rkTWFxd3C2b4Ppd{BCe3OjeR?= MWmyNO69VQ>? NXPwWVRYOTiq MkWzbY5kemWjc3XzJGxEOy2LST1Otk1i[3SrbjDyZZRqdyClb33wZZJm\CC2bzDFR3RXNU2RUzD0doVifG2nboSgc45tgQ>? MYSyOFEyPjdyNx?=
A549  NUDFe4d1SXCxcITvd4l{KEG|c3H5 NVfLc40{Oi53zszN MUCyOIg> MV3k[YNz\WG|ZYOgc5Jq\G:waX6tbY5lfWOnZDDheZRweGijZ4mgZZMhf2WubDDhcoQhVG:|czDv[kDPnM,KbTDhcJNwKG:lY4XydoVlKGS3cnnu[{BifXSxcHjh[4lkKHC{b3Pld5M> MmjrNlQyODJ3MkK=
UM-SCC-10A  NGnFcZdCeG:ydH;zbZMhSXO|YYm= Mn72OVDDvU1? MX[ybC=> M4HOepJm\HWlZYOgZZBweHSxc3nzJIlv\HWlZXSgZpkhcGmpaD3kc5NmKGm|b3HsZY51d2yjY4TvcoU> NXH2VpJuOjRyOUi3OVM>
BGC-823 NXHoeVR2SXCxcITvd4l{KEG|c3H5 NHWzUlQyOCEQvF2= NITlNY0zPGh? M1nXRZJm\HWlZYOgeIV1emGwZILpcoUucW6mdXPl[EBieG:ydH;zbZPDqA>? NYfOUWN4OjRyOUi1NVE>
Nalm-6  MmLPRZBweHSxc3nzJGF{e2G7 NIDmdGEzOM7:TR?= M{j0ZVRp Ml7XbY5pcWKrdIOgZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTNiYXP0bZZifGmxbjDhcoQhWEGUUD2xJINt\WG4YXfl MnfqNlQxOzl7Nke=
KHOS  MVnBdI9xfG:|aYOgRZN{[Xl? NX;kbplmPDEQvF2= MkLQNlRp M3r2SIJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= M3jhXFI1ODJ3M{[x
G292 Mm\5RZBweHSxc3nzJGF{e2G7 MmPQOFDPxE1? MXKyOIg> NITpSFhjdG:la4OgeIhmKGmwY4LlZZNm\CClbHXheoFo\SCxZjDjZZNx[XOnLUOgZY5lKFCDUmCgbY5lfWOnZDDifUBDSk2GM9Mg NUnoU|BXOjRyMkWzOlE>
MG-63 M3PRcWFxd3C2b4Ppd{BCe3OjeR?= MU[0NO69VQ>? MWWyOIg> MmjqZoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?= MW[yOFAzPTN4MR?=
EBV-transformed B cells M3LUcGFxd3C2b4Ppd{BCe3OjeR?= Ml;ONlDPxE1? M3fSRlJp MknOSG1UVw>? M1GyeoJtd2OtczDhcpRqNUOGOECgZY5lKGGwdHmtR2Q5PiCjboTpZo9lgS2rbnT1Z4VlKGGyb4D0c5Nqew>? MmWwNlQxODh4Mki=
IM-9 B M{j6U2Fxd3C2b4Ppd{BCe3OjeR?= NY\TXlg2OjEQvF2= NFLlNFkzcA>? NVnMVlN[TE2VTx?= M1[4WIJtd2OtczDhcpRqNUOGOECgZY5lKGGwdHmtR2Q5PiCjboTpZo9lgS2rbnT1Z4VlKGGyb4D0c5Nqew>? NU\Tcm1rOjRyMEi2Nlg>
CNE1 MX;BdI9xfG:|aYOgRZN{[Xl? NEjJV|UzOM7:TR?= M3zMZlQ5cA>? NYPVWHVM[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN? NWHzPGdkOjN7OEWwNlk>
CNE2 M1zrW2Fxd3C2b4Ppd{BCe3OjeR?= NHPUWWEzOM7:TR?= MUO0PIg> MlvXZoxw[2u|IFzLMWEucW6mdXPl[EBieG:ydH;zbZM> Mn7lNlM6QDVyMkm=
HL-60 M3ezVmFxd3C2b4Ppd{BCe3OjeR?= NFrHfok2OML3TR?= MV:xbC=> NHywRZFFVVOR M1TS[IlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEKDMUS1 NITLWHYzOzl2OEe1NS=>
L929 MknBRZBweHSxc3nzJGF{e2G7 MVexMlI26oDVNdMg{txOyqB? MUOyOIg> MY\heYdu\W62czDUUmbPuS2rbnT1Z4VlKG6nY4LvdJRwe2m|IHHu[EBifXSxcHjh[5k> MlywNlM6PDF5Nkm=
Jurkat M{SwUmNmdGxiVnnhZoltcXS7IFHzd4F6 M2PVNVLPxE1? MmTQOIg> NW[yVXp7emW4ZYLz[ZMh\3Kxd4ToJIlvcGmkaYTpc44h[W6mIN8yMYNifGWwaX6g[IVkemWjc3WgZpkhUFNvQWPB MYKyN|g6PjB4MR?=
RAW264.7  NXLwcZd6SXCxcITvd4l{KEG|c3H5 NXT1d3NOOTBizszN M3XPZlI1cA>? NH3LNGRl\WO{ZXHz[ZMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JGdC NU\kRY5nOjN6MkCyNFM>
A431  MnjPT4lv[XOnIFHzd4F6 Mnj1OFDPxE1? NFHpd2wzcA>? M{nTS4Jtd2OtczDmbZNmfGmwLXnu[JVk\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgZY5lKFCDUmC= NH;3TlUzOzhyMEC1PC=>
Jurkat NV7kS5NCS2WubDDWbYFjcWyrdImgRZN{[Xl? NHjSRnczPS1zMEFOwG0> NV7QTJdJPmh? NVTpSVRocW6qaXLpeJMhgi2IQT3DUWsucW6mdXPl[EBk\WyuIHTlZZRp M4j3PVI{QTN|NUOy
COS-7  NVy0eVMzTnWwY4Tpc44hSXO|YYm= MV21NOK2VQ>? NYHDTI5vOjSq NIjVZpZi\m[nY4TzJJRp\SCycn;j[ZN{cW6pIH;mJGFVVjG|IIfpeIgheG:ueWGgeJJi[3S| MXuyN|k{OzJyOB?=
CAL27 NXTnNo1qSXCxcITvd4l{KEG|c3H5 M4rxZlExKM7:TR?= MnfNNog> NUToNHNQe3WycILld5NmeyCFdYKtUnB{NXKnZIXj[YQhfmmjYnnsbZR6KGK7IIXwJJRwKDlyJR?= MUiyN|kyPzN7Nh?=
THP-1  M17DVmFxd3C2b4Ppd{BCe3OjeR?= NIPvV3AyOC13MN88US=> NHXEdpMzcA>? NYDRe|ZDcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nlidILpdJRwdGmmZR?= MYeyN|kxODJ7OR?=
K562 M1m5PGFxd3C2b4Ppd{BCe3OjeR?= Ml3vNlDPxE1? MlS5OFhp Mm\jbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhPC2PVR?= MkCxNlM5PzZ6Mk[=
HL-60 MUfBdI9xfG:|aYOgRZN{[Xl? MW[xNFDPxE1? MmHJNlRp MYrpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBi[mmndHHu[UBlcXSncoDlcoV{yqB? NHjGbYkzOzh4NUe3PC=>
HeLa  Mn;FRZBweHSxc3nzJGF{e2G7 NGLtXYMzOM7:TR?= MlfnNog> NFvCcVhqdmirYnn0d{BFVU2SIHnu[JVk\WRiYYDvdJRwe2m| MkPHNlM5PjN7Nk[=
U251 M4TVW2Fxd3C2b4Ppd{BCe3OjeR?= M2fCSVIx|ryP NVXoU4Q1OjSq M3;aSYlvcGmkaYTzJINie3SrY3nuJIlv\HWlZXSgS|IwVSCyaHHz[UBienKnc4SgZY5lKGGyb4D0c5Nqew>? NVT5fZBLOjN6MU[4NVY>
HL-60 MoG0RZBweHSxc3nzJGF{e2G7 MUO1NOK2VQ>? M2TMb|Rp NXW2fpV7[myxY3vzJJRp\SClbHXheoFo\SCxZjDjZZNx[XOnLUOsJE06NCCjbnSgVGFTWCCrbnT1Z4VlKGK7IE\z Mo\FNlM5ODR5ME[=
Ec-109 NYnQ[m5xSXCxcITvd4l{KEG|c3H5 NFu4XlEyOCEQvF2= MmO5OFhp MX;y[ZBz\XO|ZYOgVGUudWWmaXH0[YQhTWNvMUC5JINmdGxiYYDvdJRwe2m| MYeyN|c5OjZ2MR?=
RKO MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUO1OYI{OTBizszN M1zFRVI1cA>? MmDEbY5pcWKrdIOgeIhmKGSnY4LlZZNmKG:oIHPlcIwhfmmjYnnsbZR6KGOjdYPl[EBjgSCGQVK= MY[yN|c2QDB4NB?=
T98G NIXuZWpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUTnR21nOS1zMEFOwG0> NEPkXokzPGh? MlfGbY1xem:4ZYOgZ4VtdCC4aXHibYxqfHliY3;0doVifG2nboSge4l1cCCWUx?= NHLNdIUzOzd4OUK3OS=>
Jurkat M{\ZXmNmdGxiVnnhZoltcXS7IFHzd4F6 MnPyNVAxNTJyMN88US=> NY\Z[YlOOjSq MXXpcohq[mm2czDIZWE1KGmwZIXj[ZMh[XCxcITvd4l{KGSncHXu[IVvfCCxZjDjc45k\W62cnH0bY9vyqB? M{TOb|I{PzN{NEix
Molt-3  Mm\iRZBweHSxc3nzJGF{e2G7 NWG0[I8xPTEQvF2= MVmybC=> MYXy[YR2[2W|IH3lcIF1d26rbj3pcoR2[2WmIHHwc5B1d3Orcx?= M1K4flI{PzJ3MEGz
hMSC12 Mo\tRZBweHSxc3nzJGF{e2G7 NW\TdFZDOTByzszN NYLlSIR4PGR? NULHVJhjcW6qaXLpeJMhd3O2ZX;n[Y5q[yCldXz0eZJmNWmwZIXj[YQh[2WubDDk[YF1cCCjbnSgZ4Ft[2moaXPheIlwdg>? NU[1NFN2OjN4NUe4NlI>
HM7  MYHBdI9xfG:|aYOgRZN{[Xl? NX\he29uOjEQvF5CpC=> MWOxbC=> MlrtZoxw[2u|IHHwbYN2dGG{ZX6gRUBi[2W2YYTlMYlv\HWlZXSgZ4F{eGG|ZT2zJIFkfGm4YYTpc44h[W6mIGDBVnAh[2ynYY\h[4U> M4PuS|I{PTh|NEGy
Hep-2  NXfIcVRPSXCxcITvd4l{KEG|c3H5 MXqyNO69VcLi MYmyOIg> M3fCNmROW09? Mn7sZYxt\X[rYYTld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDzbYxq[mmwaX6= MVWyN|U5ODB|Mh?=
HSCs NXTuUGlCSXCxcITvd4l{KEG|c3H5 NV\CW4pOPTEQvF2= MWOyOIg> NVy0eVIyTE2VTx?= MoqybY5pcWKrdIOgcoltd3SrbnniMYlv\HWlZXSgSG5CKGSjbXHn[UBqdmSrY3H0[YQh[nliUFHSVEBkdGWjdnHn[S=> NWjR[WwxOjN2OUm4O|Q>
HL-60  NV7hXXJFS3m2b4TvfIlkcXS7IFHzd4F6 NYHR[25MOjEQvF5CpC=> NXPZU5ljOjSq MVPy[YR2[2W|IITo[UBkgXSxdH;4bYMh\W[oZXP0JI9nKEW{eUW= MkjKNlM1QTR2OEC=
HA NXLPeplqSXCxcITvd4l{KEG|c3H5 NIXsZnQ2OM7:TR?= MYeyOIg> MmXSd5VxeHKnc4Pld{B1cGViY3zlZZZi\2Vib3[gVGFTWCCjbnSgZ4F{eGG|ZT2zMEAuPyxiYX7kJE06KGmwZIXj[YQh[nliYn;yeIV7d22rYj;TRWhC NFXmTokzOzR5NUm1Oi=>
C666-1 NETrOm5CeG:ydH;zbZMhSXO|YYm= MYq1NO69VQ>? M1u2VVI1cA>? NWjyUodwe3WycILld5NmeyC2aHWgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G|cHHz[U0{NCBvNzygZY5lKC17IHnu[JVk\WRiYomgZo9zfGW8b33pZk9USUiD MXiyN|Q4PTl3Nh?=
Hepa1-6 MofLRZBweHSxc3nzJGF{e2G7 NFLneFA2OM7:TR?= NWnZbopLOmh? Mn;xbY5pcWKrdIOgZ5Vz[3WvaX6gZY5lKHKnc4\ldoF1em:uLXnu[JVk\WRiYYDvdJRwe2m| M1TSPVI{PDR4N{Wz
PLC/PRF/5c M4r5dWFxd3C2b4Ppd{BCe3OjeR?= MkTxOVDPxE1? NVnyZnl[OWh? NVzTN3RHeHKndnXueJMh[XCxcITvd4l{KHS{aXfn[ZJm\CCkeTDDTW4> MXqyN|Q{QDh{NB?=
HCT116 MoDFRZBweHSxc3nzJGF{e2G7 M2\KPVExOM7:TR?= NF;yUHYyNjWq NFS5SHVqdmirYnn0d{BQey2rbnT1Z4VlKGOnbHyg[IVifGh? MkHWNlM4PDR|NUO=
HCEC NGHR[4JHfW6ldHnvckBCe3OjeR?= M{Xs[|Ux|ryP NVLCcY42PzKq NXLRcFl3TE2VTx?= M3;XXpJme3SxcnXzJI9nKHSqZTDuc5Ju[WxiSFPFR{BxcGWwb4T5dIU> NWPhXIJOOjN5NEKwNVE>
Primary rat cerebral cortical neurons MXXBdI9xfG:|aYOgRZN{[Xl? NEXGZXMyODEQvF2= Mny5NYg> MljIdJJmfmWwdIOgR4QucW6mdXPl[EBieG:ydH;zbZMh[W6mIHPlcIwh\GWjdHi= MUSyN|c1OTNzNx?=
MDA-MB-231  MnXFRZBweHSxc3nzJGF{e2G7 NUXqd2dWOjYQvF2= MWmyOIg> MnPSZYJzd2ejdHXzJIN6fG:2b4jpZ4l1gSCjbnSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[U0{KGGwZDDQRXJRKGmwZIXj[YQh[nliUnez NFnGNWMzPTN|N{W0OC=>
NLRP3-Tet-on-MC/9  MlS5RZBweHSxc3nzJGF{e2G7 M3fPOVExNTRyzszN M2Dre|EzcA>? Mo\RZZR1\W63YYTld{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgR2FRWy2jc4PvZ4lifGWmIF7MVnA{KG23dHHueJMhcW5idHjlJHRmfC2xbjDzfZN1\W1? NIfaOY4zOzdyM{O4PS=>
KNS42  NFfhZ5pCeG:ydH;zbZMhSXO|YYm= MkT0OVDPxE1? MmT4NYg> M{XpRZJm\HWlZYOgZ4VtdCCmZXH0bEBidmRiY3;tdIxmfGWueTDhZo9tcXOqZXSgZ4F{eGG|ZTCzM|ch[WO2aY\peJkhcW5icnXzdI9ve2VidH:gRWJVNTJ4Mz:ySGcwdWW2Zn;ycYlvKGOxbXLpcoF1cW:w NVzhcVNqOjN4OUGxOFU>
MCF-7  Mln0RZBweHSxc3nzJGF{e2G7 MlHCNlDPxE4EoB?= MoDoO|Jp MXnpcohq[mm2czDldZVwdC1iYX7kJFQuV0iWLX3l[IlifGWmIHHwc5B1d3Orcx?= MlPtNlM3PzV4NEO=
hCMEC/D3  NVfXNFdvSXCxcITvd4l{KEG|c3H5 NXLjSppuOjYQvF2= NX;HSVZzPzKq NX\TRpV3emWmdXPld{BNfHiDIHnu[JVk\WRiYYDvdJRwe2m| M1SzW|I{PjZ3MUm4
Jurkat NHzFcmFCeG:ydH;zbZMhSXO|YYm= M2jCWVEzNjVvNUFOwG0> MYSxbC=> NIHkV|Rld3OnIHTldIVv\GWwdHz5JJN2eHC{ZYPz[ZMhW1CKLXnu[JVk\WRiUHHyMVQh[2ynYY\h[4UtKFCDUmCgZ4xm[X[jZ3WsJGRPSSCocnHncYVvfGG2aX;uMEBidmRibH;zd{Bw\iC4aXHibYxqfHl? M1KwblI{PDR{OUe2
CNE-1 NWDkZmVuSXCxcITvd4l{KEG|c3H5 MXWyNO69VcLi MlnUNlRp M3m0bIlvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi= NEPtNW0zOzR{Nki1NC=>
HONE-1 MnPQRZBweHSxc3nzJGF{e2G7 MY[yNO69VcLi M2H1XVI1cA>? M2CyTolvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi= MX:yN|QzPjh3MB?=
astrocytes cell NWHnZXNmSXCxcITvd4l{KEG|c3H5 NXP2[3hVPDEQvF2= M1nHU|Zp NIf6[nNz\WS3Y3XzJIViemy7IHHwc5B1d3OrczDpcoR2[2WmIHL5JJN1[XW{b4Pwc5JqdmV? MVuyN|QyOTd5OB?=
U-937 MXrBdI9xfG:|aYOgRZN{[Xl? MX[xNO69VQ>? MYizNI1qdg>? MX\wdoV3\W62czDUUmYucW6mdXPl[EBv\WO{b4D0c5Nqew>? MYOyN|QyODd2OB?=
MDA-MB-231 MXLBdI9xfG:|aYOgRZN{[Xl? NF;Vb4EyODEQvF2= MUSxbC=> Mo\YbY5pcWKrdIOgd4Vve2m2aYrheIlwdiC2bzDUVmFKVCC3cH;uJG1VTEhiZH;3ck1z\We3bHH0bY9v M1;FO|I{PDB6NEK5
HeLa  MXnBdI9xfG:|aYOgRZN{[Xl? NXPkOFdnOTByzszN M4XL[lJp NVnYdm9R[myxY3vzJGpTWy1zNTDJcoR2[2W|IFHwc5B1d3SrYzDD[YxtKESnYYTo NV7BV4ZQOjN|NESwOFU>
Ec109 MkDsRZBweHSxc3nzJGF{e2G7 NYPmb29POTEQvF2= M4KwPFZp NW\EUpc1[myxY3vzJIFxd3C2b4TpZ{Bkd22kaX7heIlwdiCxZjDUZZQuW22jY163JIFv\CC{YXTpZZRqd25? NWPheYlJOjN|M{i1Olg>
H460  NHzRb|lCeG:ydH;zbZMhSXO|YYm= NGTnOoMyOM7:TR?= MkfDOog> NI\XUGpjdG:la4OgZZBweHSxdHnjJINwdWKrbnH0bY9vKG:oIGTheE1UdWGlTkegZY5lKHKjZHnheIlwdg>? MV6yN|M{QDV4OB?=
HeLa  NFHh[IJCeG:ydH;zbZMhSXO|YYm= NXvGOpRVPTEQvF2= NWTBWVFJOS53aB?= M3TzRoFjem:pYYTld:KhS2iuYX35[IliNWmwZIXj[YQh[XCxcITvd4l{ NE\tUnQzOzNyM{iwOC=>
SK-HEP1 MlfVRZBweHSxc3nzJGF{e2G7 NETzNHQyODEQvF2= NVf6UGNrOWh? Mon2bY5pcWKrdIOgR5JVOSCjY4TpeoF1\WRiY3HzdIF{\S1|LDCtO{whNThuID25MEBidmRicH;sfUhCTFBvcnnic5NmMSCyb3z5cYVz[XOn NITRe2wzOzNyMk[1NC=>
QGY7701 M1TxTGFxd3C2b4Ppd{BCe3OjeR?= M3PiRVI2|ryP NYLvR25VOS53aB?= MnjYbY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIIP1Zk1IOSCyaHHz[UBqdmS3Y3XkJIJ6KESRWDCrJJF2\XKlZYTpci=> MkD6NlMzPDByNkG=
HepG2 MlzGRZBweHSxc3nzJGF{e2G7 MmPtNlDPxE1? NIjkUpk{OG2rbh?= NHjNOG1qdmirYnn0d{B1cGViZX7oZY5k\WRiY3XscEBl\WG2aDDifUBkd22kaX7l[EB1emWjdH3lcpQhd2ZiYYDp[4VvcW5iYX7kJHRTSUmO NGjyPYUzOzJ{NEKzPS=>
U87  Mn3ORZBweHSxc3nzJGF{e2G7 M4HVOFI2|ryP NYqyNYV3Omh? NXLCXmZD\GWlcnXhd4V{KGm|b3zpdZVqemm2aXflcolvKCiLU1ypMYlv\HWlZXSgZZBweHSxdHnjJINmdGxiZHXheIgtKGK3dDDuc5QhdmWlcn;0bYMh[2WubDDk[YF1cA>? MorGNlMzOjl4Mk[=
HSC-2 NHTTSWNCeG:ydH;zbZMhSXO|YYm= M2fLR|I2NzVyzszN Mki4NYg> MnvqbY5pcWKrdIOgV24uOzhvaX7keYNm\CCleYTveI95cWOrdIm= NIfjVpUzOzF3NUK0PC=>
HSC-4 M1OyNmFxd3C2b4Ppd{BCe3OjeR?= NUTqb|J{OjVxNUFOwG0> NX;3PJliOWh? MWTpcohq[mm2czDTUk0{QC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= MWOyN|E2PTJ2OB?=
CL-1 M324fGFxd3C2b4Ppd{BCe3OjeR?= MoW5NlDPxE1? MoLoNYg> NVzkZYRP[myxY3vzJG9RPDR7IHnu[JVk\WRiY3XscEBl\WG2aB?= M2rS[FI{OTNzN{iy
MEL MXHBdI9xfG:|aYOgRZN{[Xl? NFrVeHQzOM7:TR?= MWKyOIg> NWLGOIZFTE2VTx?= NVS4[WZKcW2yYXny[ZMhWDK[Nz3pcoR2[2WmIF3FUEBk\WyuIHHwc5B1d3Orcx?= NWW1Zo5XOjNyMUS4PFc>
Bel-7402  NI\HZZVE[XOyYYPlJGFkfGm4YYTpc44hSXO|YYm= MnrBOVDPxE1? Mmn2Nog> NFiySlRqdmirYnn0d{BRS0VvaX7keYNm\CCjbn;pb4l{ MnS2NlMxODh5NEK=
Eca-109 NIPx[HRCeG:ydH;zbZMhSXO|YYm= M2jMdFI2|ryP MnnTN|BucW5? M4XsT4lvcGmkaYTzJGJLNUJzMT3pcoR2[2WmIHPlcIwh\GWjdHi= NGG3d3YzOzB5Nkm2Oy=>
MEL MonIRZBweHSxc3nzJGF{e2G7 NWnZVJE{OjEQvF2= NFfST2sycA>? NW[3bHZ1TE2VTx?= NHHW[FRqdXCjaYLld{BROlh5LXnu[JVk\WRiTVXMJINmdGxiYYDvdJRwe2m| Mnf4NlMxOTR6OEe=
Bel-7402  M4XyZmFxd3C2b4Ppd{BCe3OjeR?= M4fsN|Ux|ryP NVztS2x2Omh? NYj0WmhWcW6qaXLpeJMhWEOHLXnu[JVk\WRiYX7vbYtqew>? MoLQNlMxODh5NEK=
L929 MVfGeY5kfGmxbjDBd5NigQ>? NVu2WopTOi53zszN NHvCUm8ycA>? MnLkbY5kemWjc3XzJHJKWDFiZYjwdoV{e2mxbjDhcoQh\XijY3XyZoF1\WRiVF7G{tEucW6mdXPl[EBucXSxY3jvcoRzcWGuIHT5d4Z2dmO2aX;uJIFv\CCUT2OgdJJw\HWldHnvci=> NVTVO|BNOjNyMEC1NVg>
RCC  M1;sdmNmdGxiVnnhZoltcXS7IFHzd4F6 NX;LZpNSOTByzszN NGTE[XozPGh? M1rsOZJm[2:4ZYLld{B1cGVidnnhZoltcXS7IH;mJINmdGy|IHX4dI9{\WRidH:gNVVlNVCJSkK= M4WwN|IzQTlzNEm0
NB2a/d1 NUO3dI51SXCxcITvd4l{KEG|c3H5 M4TsR|ExOM7:TR?= NI\TVYI4Omh? NVnmbHBC[XS2ZX71ZZRmeyC|dHH1do9{eG:{aX7lMYlv\HWlZXSgZ4F{eGG|ZTDhZ5Rqfmm2eTygVGFTWCxiYX7kJJRifSClbHXheoFo\Q>? Ml\hNlI6QDh3NEG=
T cell MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXHNlUuOTByzszN NYTPNplsOjSq M33OOoRwe2VvZHXw[Y5l\W62bImgbY5pcWKrdHXkJHQh[2WubDDwdo9tcW[ncnH0bY9vKG2nZHnheIVlKHSqcn;1[4ghfGinIHPvMZN1cW23bHH0bY9vKHerdHigZY51cS2FREOgZY5lKGGwdHmtR2QzQA>? MorKNlI6QDJ3M{i=
K562 M1vqV2Fxd3C2b4Ppd{BCe3OjeR?= NYPST|NwOTByzszN NH25bVUycA>? MkXSZoxw[2u|IFHico9j[X[rc3P1ceKhTi2rbnT1Z4VlKGGyb4D0c5Nqew>? MmTENlI6PzJ|N{K=
Jurkat  NVna[2hLSXCxcITvd4l{KEG|c3H5 M13rNlQx|ryP M3P3[FFp NGTvdW1i[m:uaYPo[ZMhTmG|TD3pcoR2[2WmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? M1v0SlIzQTR{N{O4
BGC-823 MVLBdI9xfG:|aYOgRZN{[Xl? MUexNFDPxE1? NW\DVI5yOWh? NGTZcFNx[XK2aXHscJkhemW|Y4Xld{Bk\WyuczDh[4FqdnO2IHThcYFo\SCxZjDkZYllgmWrbh?= M4XFbFIzQTJ4NUS1
Hep3B NUjhUlhtSXCxcITvd4l{KEG|c3H5 NIf0cI82OM7:TR?= MlTuNYg> MY\icI9kc3NiYYDvdJRwe2m|IHnu[JVk\WRiYomgTGVIS3N? M3P2NFIzQTJ|MUW0
LLC-PK1 M1rWcmFxd3C2b4Ppd{BCe3OjeR?= NHHH[XYzOM7:TR?= MXmxbC=> M3HMcZBz\X[nboTzJINqe3CuYYTpck1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFH0[|UtKGKnY3zpck0yNCCjbnSgRZRoOTJicILveIVqdnN? M2XkfFIzQDl4MEO3
A549 NIn3b|FCeG:ydH;zbZMhSXO|YYm= MlvwOVDPxE1? NFztSJUycA>? MlK4Zoxw[2u|IITo[UBDSUlvaX7keYNm\CCjcH;weI9{cXQEoB?= NXTJS4d{OjJ6OEeyNVU>
SGC-7901  MYTBdI9xfG:|aYOgRZN{[Xl? M2Pk[VEx|ryP M3vId|I1cA>? NYewclNscW6qaXLpeJMh|rJuzsKt[Ilu\XSqeXzhZ5J6dHOqaXvvcolvNWmwZIXj[YQh[XCxcITvd4l{yqB? MofLNlI5PDh3OUe=
DM6 MVXBdI9xfG:|aYOgRZN{[Xl? NX;rZox6OTByzszN M2\s[VczcA>? MYXicI9kc3NiYn;0bEBGOkZvMTDhcoQhTTKIdIKtcYVlcWG2ZXSgZ5l1d3SxeHnjbZR6 MoHXNlI5OjV|Mki=
MCF-7, MDA-MB-468, Caco-2 M3TKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILqfVE2OM7:TR?= NWPFXlRKPDiq NHrpTpFqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KHOjcH;ubY4> MmDENlI5ODB7Nki=
A2750  MX;BdI9xfG:|aYOgRZN{[Xl? NWDTcItIOjEQvF2= NIX6W4wzcA>? M1zqUWROW09? NFXjTJRjdG:la4OgZ4F{eGG|ZTDjcIVifmGpZTDkeZJqdmdiaHXs[Y5idGmwIITy[YF1dWWwdDDhcoQhemWmdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? NWHVflZkOjJ5OESzOlM>
U87  MV7BdI9xfG:|aYOgRZN{[Xl? MX:yNO69VQ>? MYeyOIg> NYC3cmRoemWmdXPld{B1cGViYYDvdJRwe2m|IILheIUhcW6mdXPl[EBjgSCSTFHC NYDvNmZ6OjJ5N{i3PFA>
HT1080 NVzrcGpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn4RmE2OM7:TR?= NHG3Nlk4\A>? NHHBXVJqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBk[XW|ZXSgZpkh[2:vYnnu[YQhfHKnYYTt[Y51KG:oIFTDRUBidmRiT13Q M1\RNlIzPzRyOUi0
A549  M4HlRmFxd3C2b4Ppd{BCe3OjeR?= NXfFfJFrPTEQvF2= MkjqNog> MUnwZZJ1cWGubImg[IVkemWjc3XzJJNw\Gm3bTDz[Yxmdmm2ZT3pcoR2[2WmIHHwc5B1d3Orcx?= NXPRXlhIOjJ5MkG4NFQ>
Primary OPC M3[yOWFxd3C2b4Ppd{BCe3OjeR?= NV3oW2ZyOc7:TR?= M4nUc|ZpNzJ2aB?= NWXifHY3emWmdXPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuczDpckBm[XKueT2gZY5lKGyjdHWtZZBweHSxc3nzM45m[3Kxc3nz NIjJSpEzOjdyN{O4OS=>
PMNs M1P2bWFxd3C2b4Ppd{BCe3OjeR?= M165XlQx|ryP NEjKZmo3cA>? NWrIUIVoTE2VTx?= MmP2doV3\XK|ZXSgeIhmKGGvb4XueEBw\iClbHXheoVlKGOjc4Dhd4UuOyC2bzDu[YFzKH[naHnjcIUhdGW4ZXzz MX2yNlY6OjV5Nx?=
A549  NFzDZndCeG:ydH;zbZMhSXO|YYm= MmHFOVDPxE1? MXWxbC=> NEPSTmJxemW4ZX70d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCEYX;oeY9{cWSnIFm= M1XwSFIzPjh5NkO1
AGS MUXBdI9xfG:|aYOgRZN{[Xl? NUfoPIFwOjEQvF2= MVGxNog> Mn\xbY5pcWKrdIOgeIhmKGGldHn2ZZRqd25ib3[gdJJwNWOjc4Dhd4UuOyCrbjDy[ZNxd26|ZTD0c{B1cGViRYTPRYMh\nKjY4Tpc44> NFjzXGMzOjZ6N{O5PC=>
shC9  NEL1OIpCeG:ydH;zbZMhSXO|YYm= NWPrSphwOTEQvF2= Ml3oNVZp MlTTZox2dnS|IGPITEBmgHC{ZYPzbY9vKGmwIIPoR|kh[2WubIOg[Zhxd3OnZDD0c{BmcXSqZYKgVGEhd3JiTGDD NETsUWkzOjZ2MUC5OC=>
primary MEFs NWLqemRmTnWwY4Tpc44hSXO|YYm= NVzkZoNGOTKq MkfaxsBqdmO{ZXHz[ZMh\XSxcH;zbYRmNWmwZIXj[YQhdWm2b3Poc45lemmjbDDt[Y1jemGwZTDk[ZBwdGG{aYrheIlwdg>? Mn25NlI3OTN5Nke=
3T9 MEFs M3XMZmZ2dmO2aX;uJGF{e2G7 NIrQbpAyPmh? NI\4O41qdmO{ZXHz[ZMh[3m2b3Podo9u\SClIILlcIVie2ViYX\0[ZIh\XSxcH;zbYRmNXS{ZXH0cYVvfA>? NWG4PWxHOjJ4MUO3Olc>
3T9 MEFs NGXBUYNHfW6ldHnvckBCe3OjeR?= MnjONVhp MlLGeZBz\We3bHH0[ZMhcW6rdHnheI9zKGOjc4Dhd4UuQSCkdYSg[I94dnKnZ4XsZZRmeyCnZn\lZ5RweiClYYPwZZNmeyCjZoTldkBmfG:yb4Pp[IUhfHKnYYTt[Y51 NXP5S5c5OjJ4MUO3Olc>
MDA-MB-231  M2XvSmFxd3C2b4Ppd{BCe3OjeR?= M1nGS|Ix|ryP M4q1clRl NWD0dnNDemWmdXPld{B1cGViY3XscEBieG:ydH;zbZMhcW6mdXPl[EBjgSCvZYTmc5JucW5idILlZZRu\W62IIfhd{B{cWewaX\pZ4FvfGy7 NEf3SIYzOjV7M{S0NS=>
C6  NHm0NYhCeG:ydH;zbZMhSXO|YYm= M3vablEx|ryP MWqyOIg> NYHqZW9S[myxY3vzJJRp\SC|dYDwdoV{e2m4ZTDl[oZm[3Rib3[geIhmKHCncITp[IUhd25idnnhZoltcXS7 NISwSpUzOjV6OEm4NC=>
HL-60  MX7BdI9xfG:|aYOgRZN{[Xl? NF\UN2QyODEQvF2= NUHRVI46OjSq M1\ybYlvcGmkaYTzJJRp\SClZXzsJIFxd3C2b4Ppd{B{\WynY4Tl[EApMylvbXXueIh6dCEQsj2oNgKHmjZrLXTp[4x2[2:yeYLhco9{cWSnwrC1 M1q4UFIzPTR4Nk[5
HL-60 NHvFOY9CeG:ydH;zbZMhSXO|YYm= NVv1NZFjOTBvOEFOwG0> NYC0THNLPGh? NYrWOJBvcW6qaXLpeJMhXEeKUT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{yqB? MUiyNlUzOzJ{OR?=
BCC NYLUeId1SXCxcITvd4l{KEG|c3H5 NHXDTIU2OM7:TR?= NXO2RWc2OWh? MnL2bY5pcWKrdIOgSGFVWy2vZXTpZZRm\CCpcn;3eIghcW6qaXLpeIlwdg>? MmK5NlI2OTl2M{[=
RAW 264.7 NH7TV4pCeG:ydH;zbZMhSXO|YYm= MV[1NE8yODEQvF2= NIf0c40ycA>? NGrsU5Bkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2czDEU24ucW6mdXPl[EBzWk6DIHPs[YF3[Wen MlmxNlI1QTF2Mk[=
K562 MXzBdI9xfG:|aYOgRZN{[Xl? NIq0enozPc7:TR?= NIPBXVIzcA>? MnXDdJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[29vdILlZZRu\W62IIfpeIgh[W23cnXud4lvKEdiYX7kJHRTSUmO M3G5PFIzPDh|N{e3
SGC-7901 M3rkVmFxd3C2b4Ppd{BCe3OjeR?= MkXXNlAh|ryPwrC= NV\1dVF5Omh? MXrheJRmdnWjdHXzJGgzVzMEoH;yJHRPTiEQsT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{KGG|IIflcIwh[XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= MnPMNlI1PzF3OEm=
PC3 M4LPZ2Fxd3C2b4Ppd{BCe3OjeR?= NGTTXmQyOM7:TR?= MVe0bC=> NHHFTYpkd3WwdHXyd{BndGG4b3PvfIllNWmwZIXj[YQh[2G|cHHz[U1z\WyjdHXkJIFxd3C2b4Ppdy=> M3q0W|IzPDdzOUe0
SMMC-7721 NFLIS2RCeG:ydH;zbZMhSXO|YYm= NVfXT457PTEQvF2= M3v4S|Q5cA>? M4XSUIF1fGWwdXH0[ZMhd1SULXnu[JVk\WRiYYDvdJRwe2m| NH7QNJkzOjR4NUizNy=>
HeLa  MmjnRZBweHSxc3nzJGF{e2G7 MljqOVDDqM7:TR?= M3nncVQwQGh? M1;JRolvcGmkaYTzJHNVWy2rbnT1Z4VlKGyjdHWtdIhie2ViYYDvdJRwfGmlIHX2[Y51ew>? M{PlXFIzPDZyNUC0
HeLa  NHjhcGhCeG:ydH;zbZMhSXO|YYm= Mm\qOVDDqM7:TR?= NUTPZ5RzOWh? NVryOVV3e3WycILld5NmeyC2aHWgSnJCWC2rbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBidm6neHnuJHYheG:|aYTpeoUh[2WubIO= NGK0fZMzOjR2OUS0NC=>
T47D  MYDBdI9xfG:|aYOgRZN{[Xl? Mnu1NVAx|ryP NHO4WmQycA>? MkHlZoxw[2u|IITo[UBo\W6ncnH0bY9vKG:oIFWtZ4FlN0OWRkKgZpkhW1SV MVeyNlQxOTF4OB?=
HeLa  M2jLVGFxd3C2b4Ppd{BCe3OjeR?= MV[zNO69VQ>? MV60bC=> NXr1e3FnyqCrbnPy[YF{\XNidHjlJIdmdmW{YXygZ4VtdCC4aXHibYxqfHliNEigbEBi\nSncjDwbI91d2S7bnHtbYMhfHKnYYTt[Y51yqB? NES0VZkzOjN7NEK0PC=>
HCC MWPBdI9xfG:|aYOgRZN{[Xl? NHnPcVkzOCEQvF5CpC=> NUnqbXBOOmh? NF72RmxifHSnboXheIV{KHSqZTDETGEhcW6mdXPl[EBi[3SrdnH0bY9vKG:oIGDBVnA> NXrQO4REOjJ|NEK3N|I>
mESCs NXvXcYozSXCxcITvd4l{KEG|c3H5 NWPsbHE2Oi53zszN M4X1dVJp MV;pcohq[mm2czD0bIUhVmGILX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbh?= NHrCNWUzOjJ6NUK3OC=>
EMT-6  M1;DVWN6fG:2b4jpZ4l1gSCDc4PhfS=> NXPlb5RQOTByzszN MWexbC=> MYfwZZJ1cWGubImgZoxw[2unZDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhe2m{YX3ld4lv\Q>? MmrPNlIzPTF7MkG=
MCF7 M3;2cWFxd3C2b4Ppd{BCe3OjeR?= NWnjc41wPTEEoN88US=> MXOxbC=> MWfpcohq[mm2czDQRUBi[3SrdnH0[YQh[2G|cHHz[U0{NCBvOTygZY5lKHCxbImoRWRRNXKrYn;z[UkheG:ueX3ldoF{\Q>? NXz2b481OjJ{MkOzOFU>
K562 NX\G[FFVSXCxcITvd4l{KEG|c3H5 MUiyNEDPxE4EoB?= MoLVOFhp NIKyd3dFVVOR NVzQOoVR[myxY3vzJIxieGG2aX7pZk1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZidnnhZoltcXS7IHHu[EBieG:ydH;zbZMhcW6mdXP0bY9v MV[yNlIyPjF3OB?=
Molt4-hyg MWHBdI9xfG:|aYOgRZN{[Xl? M1vHVVEx|ryP NIq2R2YxNjWq MnXWZoxw[2u|IH\hdo5me2:uLXnu[JVk\WRiY3HzdIF{\S1|LXzpb4Uh[WO2aY\peJk> NYXoPJZLOjZ{N{W4NVE>
HeLa NXTSS3lFSXCxcITvd4l{KEG|c3H5 MoPNNVDPxE1? MWewMlVp MVTpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUB1cGViY3;tZolv\WRidILlZZRu\W62IIfpeIgh\2:vaYPpckBPKGGwZDDUVmFKVA>? M1uySlIzOTd7Nk[x
Jurkat T Mkm5RZBweHSxc3nzJGF{e2G7 MnzDN|DPxE1? MXiwMlVp M1rRdWROW09? MmLKZoxw[2u|IITo[UB7cXKjbT3pcoR2[2WmIHHwc5B1d3Orcx?= Mo\INlIyPTl6OUi=
Neutrophil NHz2cZVCeG:ydH;zbZMhSXO|YYm= MXuyNO69VQ>? NWTHTVN1OC53aB?= MnfDZZR1\W63YYTld{B1cGVicILvMYFxd3C2b4TpZ{Bm\m[nY4Sgc4YhVWGUMR?= NH7yfoUzPjF7Nki0OC=>
HCT116 NInkWppCeG:ydH;zbZMhSXO|YYm= NFfDRVQ2OMLizszN MXKybC=> NXqydZg4emW4ZYLz[ZMhe3mwZYLnbZN1cWNiYYDvdJRwe2m|IHXm[oVkfHNib3[gZ4Vt\WOxeHniJIFv\CCQUFOtNVbDqA>? NEjST4IzOjF3OUe1Ni=>
MDA-MB-231  Mn\2RZBweHSxc3nzJGF{e2G7 Ml7hNk42NTdwNd88US=> NUf0eXNXOmh? NGHyco5qdmirYnn0d{B1cGViY3XscEBl\WG2aDDv[kBOTEFvTVKtNlMyKGOnbHzzJIlv\HWlZXSgZpkhW0SWIHnuJIEh[2:wY3XueJJifGmxbjDk[ZBmdmSnboSgcYFvdmW{ M{nod|IzOTF3NUK2
LNCaP NX30cZhTSXCxcITvd4l{KEG|c3H5 MWK0NO69VQ>? MWSybC=> MXTpcohq[mm2czDieZRmcW5iaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> NF7XdlYzOjFzNEe2OC=>
MB231 MWrBdI9xfG:|aYOgRZN{[Xl? Mof4NVAx|ryP MWexbC=> MofvSG1UVw>? NVPhW4R3[WK{b3fheIV{KHSqZTDpcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCkeTDXSWUyKGmwaHnibZRqd25uIGTSRWlNKHS{ZXH0cYVvfCxiYX7kJJRp\SClb33ibY5ifGmxbh?= M4rhfFIzOTF{OUSw
HCC38  M{HTNGFxd3C2b4Ppd{BCe3OjeR?= MXixNFDPxE1? MUKxbC=> NFj2S|lFVVOR NG\teYli[nKxZ3H0[ZMhfGinIHnu[JVkfGmxbjDv[kBk\WyuIHTlZZRpKGK7IGfFSVEhcW6qaXLpeIlwdixiVGLBTWwhfHKnYYTt[Y51NCCjbnSgeIhmKGOxbXLpcoF1cW:w MVWyNlEyOjl2MB?=
MDA-MB231 MmS2RZBweHSxc3nzJGF{e2G7 MmrEOVDDqM7:TR?= NIi1V5MzPGh? NFHMb4dFVVOR NULGc5F3[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? M17tWlIzOTBzM{O1
LNCaP MVTBdI9xfG:|aYOgRZN{[Xl? NIj4OYw2OMLizszN M{PBe|I1cA>? NGnaeWdFVVOR MXnhZpJw\2G2ZYOgZ5Vz[3WvaX6tbY5lfWOnZDDj[YxtKGSnYYTo NYfIRoNZOjJzMEGzN|U>
HCT116 MU\BdI9xfG:|aYOgRZN{[Xl? NUXIdoJWPTEEoN88US=> NXLsU5k3OjSq NVjQZ3VwTE2VTx?= NYOxbodF[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? M1\WcFIzOTBzM{O1
Ishikawa  M{K1W2Fxd3C2b4Ppd{BCe3OjeR?= M2jkUFI2|ryP MYGyOIg> MXry[YR2[2W|IHPlcIwh\GWjdHigZY5lKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IFLh[kBCOQ>? NXi0Sm5rOjJyOEi5NVg>
 YD-8  M1LC[GFxd3C2b4Ppd{BCe3OjeR?= MVOxNFDPxE1? MYGxbC=> MWDpcohq[mm2czDQUGVQNWmwZIXj[YQh[XCxcITvd4l{ MX[yNlA5PjF6Mx?=
eosinophil  MVrBdI9xfG:|aYOgRZN{[Xl? NGHOfYI6OM7:TR?= NFmxNnozPGh? NV[xdlJpcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliRnHzJIFvfGmkb3T5xsA> M1ziRVIzODd7M{O0
L929 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnGT4czNjYQvF2= NUTEW4VPOjSq NGjiU45qdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxNXB|ODDhcoQhVkZvzsrCJJRwKGG3Z33lcpQhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7 NX3ZWoIxOjJyMkewPVc>
YD-8  NViySItVSXCxcITvd4l{KEG|c3H5 MYGxNFDPxE1? M2noWVFp NIDwdnRjdG:la4OgeIhmKEeVLVjDcE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MmH5NlIxOjByN{i=
HBx NUTLXmRbSXCxcITvd4l{KEG|c3H5 M1PrO|I2|ryP NYHx[GpYPDiq MXfEUXNQ Mk\BdoVlfWOnZDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhOy2PQR?= MXSyNlAzODB5OB?=
U937  M2LuSWFxd3C2b4Ppd{BCe3OjeR?= MYC1NOKh|ryP MVuxbC=> M4nxc4lvcGmkaYTzJGhHNWmwZIXj[YQh[XCxcITvd4l{yqB? NWS1RlJlOjF7OUi3N|E>
HL60 MkjqRZBweHSxc3nzJGF{e2G7 NXj5dFNkPDEQvF2= M1HmcVQxdWmw NWq4OpRTTE2VTx?= NW\SZZBy[myxY3vzJGJPTENiY3;tdI92dmS|IHnu[JVk\SCneIDvd5Vz\SCxZjDwbI9{eGijdHnkfYx{\XKrbnWgZY5lKESQQTDmdoFodWWwdHH0bY9v MkD0NlE6QDN{OU[=
M-14 MYfBdI9xfG:|aYOgRZN{[Xl? MXuyOe69VQ>? NHr1PZMxNjWq MlnjxsBqdmirYnn0d{Bjd3SqIITo[UBkenWmZTDlfJRz[WO2LTDhcoQh[2:vcH;1coQucW6mdXPl[EBieG:ydH;zbZM> MoHCNlE6PTR7NUm=
SK-BR-3 NVvpPZF6SXCxcITvd4l{KEG|c3H5 NV7EV2tFPTEEoN88US=> M1PCZ|Jp MX;icI9kc3NiYYDvdJRwfGmlIFTORUBnemGpbXXueIF1cW:wIHnu[JVk\WRiYomgZ49u[mmwYYTpc44hd2ZiU12tNVY1KGGwZDDyZYRq[XSrb36= M1LmVlIyQTBzM{i2
MDA-MB-468 MYXBdI9xfG:|aYOgRZN{[Xl? NYLBUoozPTEEoN88US=> Ml3qNog> MknWZoxw[2u|IHHwc5B1d3SrYzDEUmEh\nKjZ33lcpRifGmxbjDpcoR2[2WmIHL5JINwdWKrbnH0bY9vKG:oIGPNMVE3PCCjbnSgdoFlcWG2aX;u M2fvRVIyQTBzM{i2

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
IRF-1 / p-STAT1 / cleaved PARP1 / cleaved-caspase3; 

PubMed: 27191889     


With the addition of Z-VAD-FMK, levels of cleaved Caspase-3 and PARP1 were decreased.

Beclin1 / Atg5 / Atg7 / LC-3I / LC-3II; 

PubMed: 27191889     


Levels of Beclin1, Atg5, Atg7 and LC3-II were decreased after IFN-γ stimulation. However, when IFN-γ was combined with the caspase inhibitor, levels of Beclin1, Atg5, Atg7 and LC3-II were not decreased as determined by the Western Blot test. 

p23 / Hsp90 / hTRET / MMP2; 

PubMed: 19740745     


Expression of Hsp90 client proteins during cell death. HeLa cells were preincubated with z-VAD-fmk (100 μM) for 1 h and exposed to various concentrations of tunicamycin (Tu, in μM) for 24 h. Cell extracts were prepared and analyzed by Western blotting. β-Actin was used as the loading control.

cyto C; 

PubMed: 17301139     


z-VAD-fmk did not inhibit cytochrome c release in RRV-infected MA104 cells (RRV: rhesus rotavirus). Mock- and RRV-infected MA104 cells either were not pretreated or were pretreated with 100 μM z-VAD-fmk for 2 h before RRV infection, and treatment was continued during infection. Fourteen hours after RRV infection, the cytosolic and heavy-membrane fractions were assayed for cytochrome c by Western blotting. Mock-infected MA104 cells were used as negative controls. Cox IV and tubulin were used as protein loading controls for the heavy-membrane and cytosolic fractions, respectively. Positions of molecular weight markers are indicated on the left.

27191889 19740745 17301139
Growth inhibition assay
Cell viability; 

PubMed: 12522090     


Inhibition of magnolol-induced apoptotic cell death by z-VAD-fmk. CH27 cells were treated with cell permeable broad-spectrum caspase inhibitor (z-VAD-fmk) 2 h prior to 80 μm magnolol treatment. Cell viability was estimated. ***P<0.001, compared with the 80 μM magnolol-treated group. 

12522090
Immunofluorescence
cytochrome c ; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Smac/DIABLO; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Endo G; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of EndoG together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

AIF; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of AIF together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

11726499 12941691
ELISA
IL-1β; 

PubMed: 26254306     


Cell-free medium supernatants were harvested at 5 h. IL-1β levels were measured by ELISA. Z-VAD-FMK was used as a positive control. Bars represent means ± sem of pooled results from 3 experiments performed in triplicate at different times.

26254306
In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

- Collapse
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID